$34.77
-0.14-0.4%
Last update: Nov 10, 10:15 AM
Maze Therapeutics Inc (MAZE) Stock Price, Quote, News & History
MAZENASDAQ
Maze Therapeutics stock drops despite Phase 2 data showing uACR reductions in APOL1 kidney disease; analysts keep bullish targets.
You can purchase shares of Maze Therapeutics (NASDAQ:MAZE) through any online brokerage.
Other companies in Maze Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Maze Therapeutics has a consensus price target of $62.73.
The stock price for Maze Therapeutics (NASDAQ: MAZE) is $34.77 last updated November 10, 2026 at 10:15 AM EST.
There are no upcoming dividends for Maze Therapeutics.
Maze Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Maze Therapeutics.
Maze Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases,...
